Key Highlights
- eGenesis secures $191M Series D financing led by Lux Capital and notable investors.
- Funding will advance lead kidney transplant product EGEN-2784 to clinical trials.
- Over 90,000 people are on the kidney transplant waitlist annually, far exceeding available organs.
- eGenesis is pioneering genome-engineered organs to end waitlist mortality.
Source: Business Wire
Notable Quotes
- “This financing demonstrates the confidence that investors have in cross-species transplantation as a potential solution to the global organ crisis and in eGenesis as the leader in this sector.” — Mike Curtis, President & CEO at eGenesis
- “What was once science fiction is now science fact. We are thrilled to support eGenesis in advancing this pivotal modality to address one of the most intractable challenges facing medicine today.” — Peter Hebert, Co-Founder and Managing Partner at Lux Capital
SoHC's Take
eGenesis is leading a transformative approach to addressing the organ shortage crisis by leveraging advanced genome editing tools. The successful close of their $191 million Series D financing reflects significant investor confidence in their innovative solutions, particularly with their lead candidate, EGEN-2784. As the company moves closer to human trials, it may redefine the future of organ transplantation and offer new hope to patients suffering from organ failure worldwide.
